AI-enabled Software To Detect Prostate Cancer Bone Metastases Clears FDA

AI-enabled Software To Detect Prostate Cancer Bone Metastases Clears FDA
5
(2)

An artificial intelligence (AI) program that aims to make it easier to identify bone metastases in men with prostate cancer has been granted 501(k) clearance by the U.S. Food and Drug Administration (FDA), its developer announced.

The program uses a neural network — a type of AI — to identify hotspots on bone scans indicative of bone metastasis, which is when cancer cells spread from the prostate and start growing in bone tissue. It also calculates the automated bone scan index or aBSI, an imaging marker that can help detect changes in bone health in men with prostate cancer.

Traditionally, bone scans are assessed manually by a clinician, a process that can be time-consuming and that may be subject to human error. The new program, owned by Lantheus Holdings and also called aBSI, offers a fast and reliable alternative to manual interpretation for detecting hotspots that indicate bone metastases.

Multiple studies have demonstrated the clinical utility of the aBSI index as a prognostic and a response imaging biomarker in patients with metastatic prostate cancer.

“aBSI has demonstrated clinical value in quantifying and managing disease progression in advanced prostate cancer patients with the potential to support critical clinical decisions,” Etienne Montagut, senior vice president of corporate development at Lantheus, said in a press release.

The program was approved to run on the Xeleris platform, an imaging platform developed by GE Healthcare. GE and Lantheus entered into a global software licensing agreement for the program in October 2019.

“Lantheus is delighted by the U.S. approval of our digital AI solution for prostate cancer, aBSI, on GE Healthcare’s platform. As a leading multinational medical technology company with deep experience in medical imaging and diagnostics, GE Healthcare presents the ideal attributes to provide global access to this unique digital solution,” Montagut said.

Erez Levy, general manager of nuclear medicine at GE Healthcare, said the global COVID-19 outbreak has demonstrated the usefulness of AI and other analytic technology.

“The pandemic has proven that data, analytics, AI and connectivity will only become more central to delivering care,” Levy said.

“For GE Healthcare, that means continuing to advance intelligent and innovative technologies, like aBSI, and deliver precision health to promote better patient outcomes around the world,” he added.

Under the terms of the 2019 agreement, Lantheus will receive tiered licensing fees from GE per license sold.

The medical imaging development company also recently submitted an application to the FDA seeking approval of PyL, an investigational imaging agent used to locate prostate cancer lesions.

“Lantheus will continue to develop AI solutions to augment and expand the utility of imaging diagnostics for precision medicine in oncology,” Montagut said.

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Total Posts: 287
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Latest Posts
  • dogs
  • coffee and prostate cancer risk
  • ADT, cardiovascular death
  • CRISPR/Cas9 and Prostate Cancer Cells

How useful was this post?

Click on a star to rate it!

Average rating 5 / 5. Vote count: 2

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?